Sugi Predict

Sugi Predict / Compounds / SCHEMBL168982

SCHEMBL168982

SCHEMBL168982

Cc1ccc(F)c(C(F)(F)F)c1

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MPL P40238 3/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ AR P10275 10/20 0.42
▸ SYK P43405 1/20 0.41
▸ CYP11B1 P15538 1/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ PDE3B Q13370 1/20 0.40
▸ PDE3A Q14432 1/20 0.40
▸ HTR2A P28223 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ KCNH2 Q12809 1/20 0.39
▸ RXRA P19793 1/20 0.38
▸ GRIN1 Q05586 1/20 0.38
▸ GRIN2B Q13224 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15117064 0.84 SMN1; SMN2 (0.41) SMN1; SMN2KCNH2RXRAGRIN1GRIN2B
SCHEMBL13906328 0.83 AR (0.59) MPLARCYP11B1CYP11B2PDE3B
SCHEMBL20384742 0.82 SMN1; SMN2 (0.44) MPLSMN1; SMN2ARSYKCYP11B1
SCHEMBL1690352 0.81 ALDH1A1 (0.44) SMN1; SMN2
SCHEMBL764426 0.81 CYP11B2 (0.53) CYP11B1CYP11B2
SCHEMBL4273522 0.80 SMN1; SMN2 (0.45) SMN1; SMN2ARSYKCYP11B1CYP11B2
SCHEMBL14195930 0.79 PDE3B (0.51) SMN1; SMN2ARSYKCYP11B1CYP11B2
SCHEMBL84053 0.78 SMN1; SMN2 (0.44) SMN1; SMN2ARSYKPDE3BPDE3A
SCHEMBL10030392 0.78 GLA (0.54) SMN1; SMN2ARSYKPDE3BPDE3A
SCHEMBL15040571 0.77 SMN1; SMN2 (0.44) SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 654 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-10-23 — — US claimed
US-8748478-B2 Sulfamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2014-06-10 — — US claimed
EP-2379521-B1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2014-01-22 — — EP claimed
US-8618150-B2 Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2013-12-31 — — US claimed
EP-2649072-A1 IMIDAZO [1, 2-A]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2013-10-16 — — EP claimed
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2013-09-12 — — US claimed
EP-2183239-B1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-08-22 — — EP claimed
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS BRANUM SHAWN T (US) 2012-07-26 — — US claimed
WO-2012078994-A1 IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2012-06-14 — — WO claimed
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2012-06-14 — — US claimed
US-8153682-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-10 — — US claimed
US-8148422-B2 Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA, NV (BE) 2012-04-03 — — US claimed
EP-2379521-A1 SULFAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2011-10-26 — — EP claimed
CN-101801949-A Sulfonamides as TRPM8 modulators JANSSEN PHARMACEUTICA NV 2010-08-11 — — CN claimed
WO-2010080397-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-07-15 — — WO claimed
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2010-06-24 — — US claimed
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, NV (BE) 2010-06-24 — — US claimed
EP-2183239-A1 SULFONAMIDES AS TRPM8 MODULATORS Janssen Pharmaceutica, N.V. (BE) 2010-05-12 — — EP claimed
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2009-10-22 — — US claimed
WO-2009012430-A1 SULFONAMIDES AS TRPM8 MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2009-01-22 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130237547-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MPL 3567/4885SMN1; SMN2 1194/4885AR 1490/4885
US-20120149699-A1 IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPV1, TRPM2 MPL 2316/4885SMN1; SMN2 442/4885AR 1914/4885
US-20100160337-A1 SULFAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MPL 3567/4885SMN1; SMN2 1194/4885AR 1490/4885
US-20120190674-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MPL 4161/4885SMN1; SMN2 643/4885AR 1959/4885
US-20140315899-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MPL 4161/4885SMN1; SMN2 643/4885AR 1959/4885
US-20100160289-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM2, TRPM5 MPL 3998/4885SMN1; SMN2 892/4885AR 1404/4885
US-20090264474-A1 SULFONAMIDES AS TRPM8 MODULATORS TRPM8, TRPM5, TRPM2 MPL 4161/4885SMN1; SMN2 643/4885AR 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.